Antibiotic adjuvants: Diverse strategies for controlling drug-resistant pathogens

Chemical Biology and Drug Design

Volumn 85, Issue 1, 2015, Pages 56-78

  Gill, Erin E ^a   Franco, Octavio L ^b,c   Hancock, Robert E W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Centro de Analises Proteomicas e Bioquimicas   (Brazil)

^c UNIVERSIDADE CATÓLICA DOM BOSCO   (Brazil)

Author keywords

antimicrobial peptide; antivirulence; efflux pump; immunomodulatory peptide; outer membrane permeabilizer; phage therapy; probiotic; quorum sensing; type III secretion system; lactamase

Indexed keywords

7 OXO N (4 PIPERIDINYL) 1,6 DIAZABICYCLO[3.2.1]OCTANE 2 CARBOXAMIDE; 7 [3 (1 AMINOCYCLOPROPYL) 1 PYRROLIDINYL] 1 (2 FLUOROCYCLOPROPYL) 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; ANTIBIOTIC AGENT; AVIBACTAM; AZTREONAM; BACTERIAL TOXIN; BACTERIAL VACCINE; CARBENICILLIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; ERYTHROMYCIN; FUSIDIC ACID; GARENOXACIN; IMIPENEM; IMMUNOMODULATING AGENT; MEROPENEM; N ACYLHOMOSERINE LACTONE; NALIDIXIC ACID; NOVOBIOCIN; POLYPEPTIDE ANTIBIOTIC AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT; QUINOLONE DERIVATIVE; SULBACTAM; TAZOBACTAM; TOBRAMYCIN; TRIMETHOPRIM; UNINDEXED DRUG; ANTIINFECTIVE AGENT; BACTERIAL SECRETION SYSTEM; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL OUTER MEMBRANE; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; NONHUMAN; ORAL REHYDRATION THERAPY; QUORUM SENSING; TYPE II SECRETION SYSTEM; TYPE III SECRETION SYSTEM; BACTERIAL SECRETION SYSTEM; BIOLOGICAL MODEL; DRUG EFFECTS;

BACTERIA (MICROORGANISMS);

ADJUVANTS, PHARMACEUTIC; ANTI-INFECTIVE AGENTS; BACTERIAL SECRETION SYSTEMS; DRUG RESISTANCE, BACTERIAL; HUMANS; MODELS, BIOLOGICAL;

EID: 84918777580     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12478     Document Type: Article

References (179)

1. Clatworthy A.E., Pierson E., Hung D.T., (2007) Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol; 3: 541-548.
2. Liu Y.C., Li Y.S., Lyu S.Y., Hsu L.J., Chen Y.H., Huang Y.T., Chan H.C., Huang C.J., Chen G.H., Chou C.C., Tsai M.D., Li T.L., (2011) Interception of teicoplanin oxidation intermediates yields new antimicrobial scaffolds. Nat Chem Biol; 7: 304-309.
3. Kristiansson E., Fick J., Janzon A., Grabic R., Rutgersson C., Weijdegard B., Soderstrom H., Larsson D.G., (2011) Pyrosequencing of antibiotic-contaminated river sediments reveals high levels of resistance and gene transfer elements. PLoS ONE; 6: e17038.
4. CDC (2013) Antibiotic resistance threats in the United States, 2013. www.cdc.gov/drugresistance/threat-report-2013/
5. Hogberg L.D., Heddini A., Cars O., (2010) The global need for effective antibiotics: challenges and recent advantages. Trends Pharmacol Sci; 31: 509-515.
6. FDA (2014) FDA news release: FDA approves dalvance to treat skin infections. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm398724.htm.
7. Corey G.R., Kabler H., Mehra P., Gupta S., Overcash J.S., Porwal A., Giordano P., Lucasti C., Perez A., Good S., Jiang H., Moeck G., O'Riordan W., SOLO I Investigators (2014) Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med; 370: 2180-2190.
8. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., Scheld M., Spellberg B., Bartlet J., (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis; 48: 1-12.
9. Higgins P.G., Dammhayn C., Hackel M., Seifert H., (2010) Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother; 65: 233-238.
10. van Duin D., Kaye K.S., Neuner E.A., Bonomo R.A., (2013) Carbapenem-resistant enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis; 75: 115-120.
11. Spellberg B., Blaser M., Guidos R.J., Boucher H.W., Bradley J.S., Eisenstein B.I., Gerding D., Lynfield R., Reller L.B., Rex J., Schwartz D., Septimus E., Tenover F.C., Gilbert D.N., (2011) Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis; 52: S397-S428.
12. Shlaes D.M., (2013) New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann NY Acad Sci; 1277: 105-114.
13. Abuzaid A., Hamouda A., Amyes S.G., (2012) Klebsiella pneumoniae susceptibility to biocides and its association with cepA, qacΔE and qacE efflux pump genes and antibiotic resistance. J Hosp Infect; 81: 87-91.
14. Urakawa H., Yamada K., Komagoe K., Ando S., Oku H., Katsu T., Matsuo I., (2010) Structure-activity relationships of bacterial outer-membrane permeabilizers based on polymyxin B heptapeptides. Bioorg Med Chem Lett; 20: 1771-1775.
15. Bush K., (2012) Improving known classes of antibiotics: an optimistic approach for the future. Curr Opin Pharmacol; 12: 527-534.
16. Pucci M.J., Bush K., (2013) Investigational antimicrobial agents of 2013. Clin Microbiol Rev; 26: 792-821.
17. Palzkill T., (2013) Metallo-β-lactamase structure and function. Ann N Y Acad Sci; 1277: 91-104.
18. Bush K., Jacoby G.A., Medeiros A.A., (1995) A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother; 39: 1211-1233.
19. Stachyra T., Pechereau M.C., Bruneau J.M., Claudon M., Frere J.M., Miossec C., Coleman K., Black M.T., (2010) Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor. Antimicrob Agents Chemother; 54: 5132-5138.
20. Ehmann D.E., Jahic H., Ross P.L., Gu R.F., Hu J., Kern G., Walkup G.K., Fisher S.L., (2012) Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc Natl Acad Sci USA; 109: 11663-11668.
21. Levasseur P., Girard A.M., Claudon M., Goossens H., Black M.T., Coleman K., Miossec C., (2012) In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother; 56: 1606-1608.
22. Flamm R.K., Farrell D.J., Sader H.S., Jones R.N., (2014) Ceftazidime/avibactam activity tested against gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). J Antimicrob Chemother; 69: 1589-1598.
23. ®. Bioorg Med Chem Lett; 24: 780-785.
24. Hecker S.J., Reddy K.R., Totrov M., Hirst G.C., Lomovskaya O., Griffith D.C., King P., Tsivkovski R., Sun D., Sabet M., Taraz Z., Dudley M.N., (2012) Discovery of RPX7009, a broad-spectrum beta-lactamase inhibitor with utility versus class A serine carbapenemases. Abstr 52nd Intersci Conf Antimicrob Agents Chemother: http://www.icaac.org/.
25. Winkler M.L., Rodkey E.A., Taracila M.A., Drawz S.M., Bethel C.R., Papp-Wallace K.M., Smith K.M., Xu Y., Dwulit-Smith J.R., Romagnoli C., Caselli E., Prati F., van den Akker F., Bonomo R.A., (2013) Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase. J Med Chem; 56: 1084-1097.
26. Mondon M., Hur S., Vadlamani G., Rodrigues P., Tsybina P., Oliver A., Mark B.L., Vocadlo D.J., Blériot Y., (2013) Selective trihydroxyazepane NagZ inhibitors increase sensitivity of Pseudomonas aeruginosa to β-lactams. Chem Commun (Camb); 49: 10983-10985.
27. Rodkey E.A., Winkler M.L., Bethel C.R., Pagadala S.R., Buynak J.D., Bonomo R.A., van den Akker F., (2014) Penam sulfones and β-lactamase inhibition: SA2-13 and the importance of the C2 side chain length and composition. PLoS ONE; 9: e85892.
28. Gan M., Liu Y., Bai Y., Guan Y., Li L., Gao R., He W., You X., Li Y., Yu L., Xiao C., (2013) Polyketides with New Delhi metallo-β-lactamase 1 inhibitory activity from Penicillium sp. J Nat Prod; 76: 1535-1540.
29. Yamada K., Yanagihara K., Kaku N., Harada Y., Migiyama Y., Nagaoka K., Morinaga Y., Nakamura S., Imamura Y., Miyazaki T., Izumikawa K., Kakeya H., Hasegawa H., Yasuoka A., Kohno S., (2013) In vivo efficacy of biapenem with ME1071, a novel metallo-β-lactamase (MBL) inhibitor, in a murine model mimicking ventilator-associated pneumonia caused by MBL-producing Pseudomonas aeruginosa. Int J Antimicrob Agents; 42: 238-243.
30. Higgins P.G., Stefanik D., Page M.G., Hackel M., Seifert H., (2012) In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non- susceptible Acinetobacter baumannii. J Antimicrob Chemother; 67: 1167-1169.
31. Bush K., Macielag M.J., (2010) New β-lactam antibiotics and β-lactamase inhibitors. Expert Opin Ther Pat; 20: 1277-1293.
32. Tilvawala R., Pratt R.F., (2013) Kinetics of action of a two-stage pro-inhibitor of serine β-lactamases. Biochemistry; 52: 7060-7070.
33. King A.M., Reid-Yu S.A., Wang W., King D.T., De Pascale G., Strynadka N.C., Walsh T.R., Coombes B.K., Wright G.D., (2014) Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance. Nature; 510: 503-506.
34. Zhang J.I., Chen Y.P., Miller K.P., Ganewatta M.S., Bam M., Yan Y., Nagarkatti M., Decho A.W., Tang C., (2014) Antimicrobial metallopolymers and their bioconjugates with conventional antibiotics against multidrug-resistant bacteria. J Am Chem Soc; 136: 4873-4876.
35. Yuan J., Chow D.C., Huang W., Palzkill T., (2011) Identification of a β-lactamase inhibitory protein variant that is a potent inhibitor of Staphylococcus PC1 β-lactamase. J Mol Biol; 406: 730-744.
36. Chen X., Li L., Chen S., Xu Y., Xia Q., Guo Y., Liu X., Tang Y., Zhang T., Chen Y., Yang C., Shui W., (2013) Identification of inhibitors of the antibiotic-resistance target New Delhi metallo-β-lactamase 1 by both nanoelectrospray ionization mass spectrometry and ultrafiltration liquid chromatography/mass spectrometry approaches. Anal Chem; 85: 7957-7965.
37. Sohier J.S., Laurent C., Chevigné A., Pardon E., Srinivasan V., Wernery U., Lassaux P., Steyaert J., Galleni M., (2013) Allosteric inhibition of VIM metallo-β-lactamases by a camelid nanobody. Biochem J; 450: 477-486.
38. Ripoll A., Galán J.C., Rodríguez C., Tormo N., Gimeno C., Baquero F., Martínez-Martínez L., Cantõn R., SEIMC Quality Control Study Group (2014) Detection of resistance to beta-lactamase inhibitors in strains with CTX-M beta-lactamases: a multicenter external proficiency study using a well-defined collection of Escherichia coli strains. J Clin Microbiol; 52: 122-129.
39. Biot F.V., Valade E., Garnotel E., Chevalier J., Villard C., Thibault F.M., Vidal D.R., Pagès J.M., (2011) Involvement of the efflux pumps in chloramphenicol selected strains of Burkholderia thailandensis: proteomic and mechanistic evidence. PLoS ONE; 6: e16892.
40. Biot F.V., Lopez M.M., Poyot T., Neulat-Ripoll F., Lignon S., Caclard A., Thibault F.M., Peinnequin A., Pagès J.M., Valade E., (2013) Interplay between three RND efflux pumps in doxycycline-selected strains of Burkholderia thailandensis. PLoS ONE; 8: e84068.
41. Lamers R.P., Cavallari J.F., Burrows L.L., (2013) The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) permeabilizes the outer membrane of gram-negative bacteria. PLoS ONE; 8: e60666.
42. Kumar A., Schweizer H.P., (2005) Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliv Rev; 57: 1486-1513.
43. Ince D., Zhang X., Silver L.C., Hooper D.C., (2002) Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob Agents Chemother; 46: 3370-3380.
44. Strahilevitz J., Truong-Bolduc Q.C., Hooper D.C., (2005) DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases. Antimicrob Agents Chemother; 49: 5051-5057.
45. da Silva P.E.A., Von Groll A., Martin A., Palomino J.C., (2011) Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol; 63: 1e9.
46. Roy S.K., Kumari N., Gupta S., Pahwa S., Nandanwar H., Jachak S.M., (2013) 7-Hydroxy-(E)-3-phenylmethylene-chroman-4-one analogues as efflux pump inhibitors against Mycobacterium smegmatis mc 155. Eur J Med Chem; 66: 499-507.
47. Paulasova P., Pellestor F., (2004) The peptide nucleic acids (PNAs): a new generation of probes for genetic and cytogenetic analyses. Ann Genet; 47: 349-358.
48. Jeon B., Zhang Q., (2009) Sensitization of Campylobacter jejuni to fluoroquinolone and macrolide antibiotics by antisense inhibition of the Cme- ABC multidrug efflux transporter. J Antimicrob Chemother; 63: 946-948.
49. Mu Y., Shen Z., Jeon B., Dai L., Zhang Q., (2013) Synergistic effects of anti-CmeA and anti-CmeB peptide nucleic acids on sensitizing Campylobacter jejuni to antibiotics. Antimicrob Agents Chemother; 57: 4575-4577.
50. Oh E., Zhang Q., Jeon B., (2014) Target optimization for peptide nucleic acid (PNA)-mediated antisense inhibition of the CmeABC multidrug efflux pump in Campylobacter jejuni. J Antimicrob Chemother; 69: 375-380.
51. Noumedem J.A., Mihasan M., Kuiate J.R., Stefan M., Cojocaru D., Dzoyem J.P., Kuete V., (2013) In vitro antibacterial and antibiotic-potentiation activities of four edible plants against multidrug-resistant gram-negative species. BMC Complement Altern Med; 13: 190.
52. Lacmata S.T., Kuete V., Dzoyem J.P., Tankeo S.B., Teke G.N., Kuiate J.R., Pages J.M., (2012) Antibacterial activities of selected Cameroonian plants and their synergistic effects with antibiotics against bacteria expressing MDR phenotypes. Evid Based Complement Alternat Med; 2012: 623723.
53. Hancock R.E.W., (1985) The Pseudomonas aeruginosa outer membrane permeability barrier and how to overcome it. Antibiot Chemother; 36: 95-102.
54. Hancock R.E.W., (1997) Peptide antibiotics. Lancet; 349: 418-422.
55. Hancock R.E.W., Wong P.G.W., (1984) Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother; 26: 48-52.
56. Scott M.G., Yan H., Hancock R.E.W., (1999) Biological properties of structurally related α-helical cationic antimicrobial peptides. Infect Immun; 67: 2005-2009.
57. Savage P.B., (2001) Multidrug-resistant bacteria: overcoming antibiotic permeability barriers of gram-negative bacteria. Ann Med; 33: 167-171.
58. Schmidt E.J., Boswell J.S., Walsh J.P., Schellenberg M.M., Winter T.W., Li C., Allman G.W., Savage P.B., (2001) Activities of cholic acid-derived antimicrobial agents against multidrug-resistant bacteria. J Antimicrob Chemother; 47: 671-674.
59. Vaara M., (1991) Agents that increase the permeability of the outer membrane. Microbiol Rev; 56: 395-411.
60. Briers Y., Walmagh M., Lavigne R., (2011) Use of bacteriophage endolysin EL188 and outer membrane permeabilizers against Pseudomonas aeruginosa. J Appl Microbiol; 110: 778-785.
61. Ando M., Kamei R., Komagoe K., Inoue T., Yamada K., Katsu T., (2012) In situ potentiometric method to evaluate bacterial outer membrane-permeabilizing ability of drugs: example using antiprotozoal diamidines. J Microbiol Methods; 91: 497-500.
62. Kwon D.H., Lu C.D., (2006) Polyamines increase antibiotic susceptibility in Pseudomonas aeruginosa. Antimicrob Agents Chemother; 50: 1623-1627.
63. Guha A., Choudhury A., Unni B.G., Roy M.K., (2002) Effect of outer-membrane permeabilizers on the activity of antibiotics and plant extracts against Pseudomonas aeruginosa. Folia Microbiol (Praha); 47: 379-384.
64. Chatterjee S., Bijsmans I.T., van Mil S.W., Augustijns P., Annaert P., (2014) Toxicity and intracellular accumulation of bile acids in sandwich-cultured rat hepatocytes: role of glycine conjugates. Toxicol In Vitro; 28: 218-230.
65. de la Fuente-Núñez C., Reffuveille F., Haney E.F., Strauss S.K., Hancock R.E.W., (2014) Broad-spectrum anti-biofilm peptide that targets a cellular stress response. PLoS Pathog; 10: e1004152.
66. Reffuveille F., de la Fuente-Núñez C., Mansour S., Hancock R.E.W., (2014) A broad-spectrum anti-biofilm peptide enhances action against bacterial biofilms. Antimicrob Agents Chemother; 58: 5363-5371.
67. Overhage J., Campisano A., Bains M., Torfs E.C.W., Rehm B.H.A., Hancock R.E.W., (2008) Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun; 76: 4176-4182.
68. de la Fuente-Núñez C., Korolik V., Bains M., Nguyen U., Breidenstein E.B.M., Horsman S., Lewenza S., Burrows L., Hancock R.E.W., (2012) Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimicrob Agents Chemother; 56: 2696-2704.
69. de la Fuente-Núñez C., Reffuveille F., Fernández L., Hancock R.E.W., (2013) Bacterial biofilm development as a multicellular adaptation: antibiotic resistance and new therapeutic strategies. Curr Opinion Microbiol; 16: 580-589.
70. Ho Sui S.J., Fedynak A., Hsiao W.W., Langille M.G., Brinkman F.S., (2009) The association of virulence factors with genomic islands. PLoS ONE; 4: e8094.
71. Rasko D.A., Sperandio V., (2010) Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov; 9: 117-128.
72. Fernebro J., (2011) Fighting bacterial infections-future treatment options. Drug Resist Update; 14: 125-139.
73. Antunes L.C., Ferreira R.B., Buckner M.M., Finlay B.B., (2010) Quorum sensing in bacterial virulence. Microbiology; 156: 2271-2282.
74. Gilbert K.B., Kim T.H., Gupta R., Greenberg E.P., Schuster M., (2009) Global position analysis of the Pseudomonas aeruginosa quorum-sensing transcription factor LasR. Mol Microbiol; 73: 1072-1085.
75. Schuster M., Lostroh C.P., Ogi T., Greenberg E.P., (2003) Identification, timing, and signal specificity of Pseudomonas aeruginosa quorum-controlled genes: a transcriptome analysis. J Bacteriol; 185: 2066-2079.
76. Deziel E., Gopalan S., Tampakaki A.P., Lepine F., Padfield K.E., Saucier M., Xiao G., Rahme L.G., (2005) The contribution of MvfR to Pseudomonas aeruginosa pathogenesis and quorum sensing circuitry regulation: multiple quorum sensing-regulated genes are modulated without affecting lasRI, rhlRI or the production of N-acyl-L-homoserine lactones. Mol Microbiol; 55: 998-1014.
77. de Kievit T.R., Iglewski B.H., (2000) Bacterial quorum sensing in pathogenic relationships. Infect Immun; 68: 4839-4849.
78. Lequette Y., Lee J.H., Ledgham F., Lazdunski A., Greenberg E.P., (2006) A distinct QscR regulon in the Pseudomonas aeruginosa quorum-sensing circuit. J Bacteriol; 188: 3365-3370.
79. Latifi A., Foglino M., Tanaka K., Williams P., Lazdunski A., (1996) A hierarchical quorum-sensing cascade in Pseudomonas aeruginosa links the transcriptional activators LasR and RhIR (VsmR) to expression of the stationary-phase sigma factor RpoS. Mol Microbiol; 21: 1137-1146.
80. Diggle S.P., Cornelis P., Williams P., Camara M., (2006) 4-quinolone signalling in Pseudomonas aeruginosa: old molecules, new perspectives. Int J Med Microbiol; 296: 83-91.
81. Jimenez P.N., Koch G., Thompson J.A., Xavier K.B., Cool R.H., Quax W.J., (2012) The multiple signaling systems regulating virulence in Pseudomonas aeruginosa. Microbiol Mol Biol Rev; 76: 46-65.
82. Davies D.G., Parsek M.R., Pearson J.P., Iglewski B.H., Costerton J.W., Greenberg E.P., (1998) The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science; 280: 295-298.
83. Rumbaugh K.P., Griswold J.A., Iglewski B.H., Hamood A.N., (1999) Contribution of quorum sensing to the virulence of Pseudomonas aeruginosa in burn wound infections. Infect Immun; 67: 5854-5862.
84. O'Loughlin C.T., Miller L.C., Siryaporn A., Drescher K., Semmelhack M.F., Bassler B.L., (2013) A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation. Proc Natl Acad Sci USA; 110: 17981-17986.
85. Tan S.Y., Chua S.L., Chen Y., Rice S.A., Kjelleberg S., Nielsen T.E., Yang L., Givskov M., (2013) Identification of five structurally unrelated quorum-sensing inhibitors of Pseudomonas aeruginosa from a natural-derivative database. Antimicrob Agents Chemother; 11: 5629-5641.
86. Sully E.K., Malachowa N., Elmore B.O., Alexander S.M., Femling J.K., Gray B.M., DeLeo F.R., Otto M., Cheung A.L., Edwards B.S., Sklar L.A., Horswill A.R., Hall P.R., Gresham H.D., (2014) Selective chemical inhibition of agr quorum sensing in Staphylococcus aureus promotes host defense with minimal impact on resistance. PLoS Pathog; 10: e1004174.
87. Hentzer M., Riedel K., Rasmussen T.B., Heydorn A., Andersen J.B., Parsek M.R., Rice S.A., Eberl L., Molin S., Holby N., Kjelleberg S., Givskov M., (2002) Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology; 148: 87-102.
88. Hentzer M., Wu H., Andersen J.B., Riedel K., Rasmussen T.B., Bagge N., Kumar N., et al,. (2003) Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J; 22: 3803-3815.
89. Pustenly C., Albers A., Buldt-Karentzopoulos K., Parschat K., Chhabra S.R., Camara M., Williams P., Fetzner S., (2009) Dioxygenase-mediated quenching of quinolone-dependent quorum sensing in Pseudomonas aeruginosa. Chem Biol; 12: 1259-1267.
90. Uroz S., Chhabra S.R., Camara M., Williams P., Oger P., Dessaux Y., (2005) N-Acylhomoserine lactone quorum-sensing molecules are modified and degraded by Rhodococcus erythropolis W2 by both amidolytic and novel oxidoreductase activities. Microbiol; 151: 3313-3322.
91. Chow J.Y., Yang Y., Tay S.B., Chua K.L., Yew W.S., (2014) Disruption of biofilm formation by the human pathogen Acinetobacter baumannii using engineered quorum-quenching lactonases. Antimicrob Agents Chemother; 58: 1802-1805.
92. Christensen Q.H., Grove T.L., Booker S.J., Greenberg E.P., (2013) A high-throughput screen for quorum-sensing inhibitors that target acyl-homoserine lactone synthases. Proc Natl Acad Sci USA; 110: 13815-13820.
93. Schiavo G., van der Goot G.F., (2001) The bacterial toxin toolkit. Nat Rev Mol Cell Biol; 2: 530-537.
94. Endo Y., Tsurugi K., Yutsudo T., Takeda Y., Ogasawara T., Igarashi K., (1988) Site of action of a vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem; 171: 45-50.
95. Orth P., Xiao L., Hernandez L.D., Reichert P., Sheth P.R., Beaumont M., Yang X., et al,. (2014) Mechanism of action and epitopes of Clostridium difficile toxin B neutralizing antibody bezotoxumab revealed by x-ray crystallography. J Biol Chem; 289: 18008-18021.
96. Berube B.J., Wardenburg J.B., (2013) Staphylococcus aureus alpha-toxin: nearly a century of intrigue. Toxins; 5: 1140-1166.
97. Lopez E.L., Contrini M.M., Glatstein E., Gonzalez Ayala S., Sontoro R., Allende D., Ezcurra G., et al,. (2010) Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with shiga-like toxin producing Escherichia coli. Antimicrob Agents Chemother; 54: 239-243.
98. Lowy I., Molrine D.C., Leav B.A., Blair B.M., Baxter R., Berding D.N., Nichol G., Thomas W.D. Jr, Leney M., Sloan S., Hay C.A., Ambrosino D.M., (2010) Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med; 362: 197-205.
99. Nivaskumar M., Francetic O., (2014) Type II secretion system: a magic beanstalk or a protein escalator. Biochim Biophys Acta; 1843: 1568-1577.
100. Korotkov K.V., Sandkvist M., Hol W.G., (2012) The type II secretion system: biogenesis, molecular architecture and mechanism. Nat Rev Microbiol; 10: 336-351.
101. Braun P., de Groot A., Bitter W., Tommassen J., (1998) Secretion of elastinolytic enzymes and their propeptides by Pseudomonas aeruginosa. J Bacteriol; 180: 3467-3469.
102. Voulhoux R., Ball G., Ize B., Vasil M.L., Lazdunski A., Wu L.F., Filloux A., (2001) Involvement of the twin-arginine translocation system in protein secretion via the type II pathway. EMBO J; 20: 6735-6741.
103. Baldi D.L., Higginson E.E., Hocking D.M., Praszkier J., Cavaliere R., James C.E., Bennett-Wood V., Azzopardi K.I., Turnbull L., Lithgow T., Robins-Browne R.M., Witchurch C.B., Tauschek M., (2012) The type II secretion system and its ubiquitous lipoprotein substrate, SslE, are required for biofilm formation and virulence of enteropathogenic Escherichia coli. Infect Immun; 80: 2042-2052.
104. Moir D.T., Di M., Wong E., Moore R.A., Schweizer H.P., Woods D.E., Bowlin T.L., (2011) Development and application of a cellular, gain-of-signal, bioluminescent reporter screen for inhibitors of type II secretion in Pseudomonas aeruginosa and Burkholderia pseudomallei. J Biomol Screen; 16: 694-705.
105. Segers K., Anne J., (2011) Traffic jam at the bacterial sec translocase: targeting the SecA nanomotor by small-molecule inhibitors. Chem Biol; 18: 685-698.
106. Chatterjee S., Chaudhury S., McShan A.C., Kaur K., De Guzman R.N., (2013) Structure and biophysics of type III secretion in bacteria. Biochemistry; 52: 2508-2517.
107. Engel J., Balachandran P., (2009) Role of Pseudomonas aeruginosa type III effectors in disease. Curr Opin Microbiol; 12: 61-66.
108. Dean P., (2011) Functional domains and motifs of bacterial type III effector proteins and their roles in infection. FEMS Microbiol Rev; 35: 1100-1125.
109. Yamazaki A., Li J., Zeng Q., Khokhani D., Hutchins W.C., Yost A.C., Biddle E., Toone E.J., Chen X., Yang C.H., (2012) Derivatives of plant phenolic compound affect the type III secretion system of Pseudomonas aeruginosa via a GacS-GacA two-component signal transduction system. Antimicrob Agents Chemother; 56: 36-43.
110. Kauppi A.M., Nordfelth R., Uvell H., Wolf-Watz H., Elofsson M., (2003) Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem Biol; 10: 241-249.
111. Tree J.J., Wang D., McInally C., Mahajan A., Layton A., Houghton I., Elofsson M., Stevens M.P., Gally D.L., Roe A.J., (2009) Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in Escherichia coli O157:H7. Infect Immun; 77: 4209-4220.
112. Wang D., Zetterstrom C.E., Gabrielsen M., Beckham K.S., Tree J.J., Macdonald S.E., Byron O., et al,. (2011) Identification of bacterial target proteins for the salicylidene acylhydrazide class of virulence-blocking compounds. J Biol Chem; 286: 29922-29931.
113. Larzabal M., Zotta E., Ibarra C., Rabinovitz B.C., Vilte D.A., Mercado E.C., Cataldi A., (2013) Effect of coiled-coil peptides on the function of the type III secretion system-dependent activity of enterohemorragic Escherichia coli O157:H7 and Citrobacter rodentium. Int J Med Microbiol; 303: 9-15.
114. Larzabal M., Mercado E.C., Vilte D.A., Salazar-Gonzalez H., Cataldi A., Navarro-Garcia F., (2010) Designed coiled-coil peptides inhibit the type three secretion system of enteropathogenic Escherichia coli. PLoS ONE; 5: e9046.
115. Kimura K., Iwatsuki M., Nagai T., Matsumoto A., Takahashi Y., Shiomi K., Omura S., Abe A., (2011) A small-molecule inhibitor of the bacterial type III secretion system protects against in vivo infection with Citrobacter rodentium. J Antibiot; 64: 197-203.
116. Hogg T., Mesters J.R., Hilgenfeld R., (2002) Inhibitory mechanisms of antibiotics targeting elongation factor Tu. Curr Protein Pept Sci; 3: 121-131.
117. Kohler T., Perron G.G., Buckling A., van Delden C., (2010) Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa. PLoS Pathog; 6: e1000883.
118. Maeda T., Garcia-Contreras R., Pu M., Sheng L., Garcia L.R., Tomas M., Wood T.K., (2012) Quorum quenching quandary: resistance to anti-virulence compounds. ISME J; 6: 493-501.
119. Kumar H., Kawai T., Akira S., (2011) Pathogen recognition by the innate immune system. Int Rev Immunol; 30: 16-34.
120. Regan T., Nally K., Carmody R., Houston A., Shanahan F., Macsharry J., Brint E., (2013) Identification of TLR10 as a key mediator of the inflammatory response to Listeria monocytogenes in intestinal epithelial cells and macrophages. J Immunol; 191: 6084-6092.
121. Schreibelt G., Tel J., Sliepen K.H., Benitez-Ribas D., Figdor C.G., Adema G.J., de Vries I.J., (2010) Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother; 59: 1573-1582.
122. Orr M.T., Beebe E.A., Hudson T.E., Moon J.J., Fox C.B., Reed S.G., Coler R.N., (2014) A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. PLoS ONE; 9: e83884.
123. Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., Akira S., Ahmed R., Pulendran B., (2006) Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med; 203: 413-424.
124. Schreibelt G., Benitez-Ribas D., Schuurhuis D., Lambeck A.J., van Hout-Kuijer M., Schaft N., Punt C.J., Figdor C.G., Adema G.J., de Vries I.J., (2010) Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood; 116: 564-574.
125. De Y., Chen Q., Schmidt A.P., Anderson G.M., Wang J.M., Wooters J., Oppenheim J.J., Chertov O., (2000) LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med; 192: 1069-1074.
126. Zheng Y., Niyonsaba F., Ushio H., Nagaoka I., Ikeda S., Okumura K., Ogawa H., (2007) Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human alpha-defensins from neutrophils. Br J Dermatol; 157: 1124-1131.
127. Mookherjee N., Brown K.L., Bowdish D.M., Doria S., Falsafi R., Hokamp K., Roche F.M., Mu R., Doho G.H., Pistolic J., Powers J.P., Bryan J., Brinkman F.S., Hancock R.E.W., (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol; 176: 2455-2464.
128. Nijnik A., Pistolic J., Wyatt A., Tam S., Hancock R.E.W., (2009) Human cathelicidin peptide LL-37 modulates the effects of IFN-gamma on APCs. J Immunol; 183: 5788-5798.
129. Koczulla R., von Degenfeld G., Kupatt C., Krotz F., Zahler S., Gloe T., Issbrucker K., et al,. (2003) An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest; 111: 1665-1672.
130. Shaykhiev R., Beisswenger C., Kandler K., Senske J., Puchner A., Damm T., Behr J., Bals R., (2005) Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am J Physiol Lung Cell Mol Physiol; 289: L842-L848.
131. Steinstraesser L., Hirsch T., Schulte M., Kueckelhaus M., Jacobsen F., Mersch E.A., Stricker I., Afacan N., Jenssen H., Hancock R.E.W., Kindrachuk J., (2012) Innate defense regulator peptide 1018 in wound healing and wound infection. PLoS ONE; 7: e39373.
132. Cirioni O., Giacometti A., Ghiselli R., Bergnach C., Orlando F., Silvestri C., Mocchegiani F., Licci A., Skerlavaj B., Rocchi M., Saba V., Zanetti M., Scalise G., (2006) LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother; 50: 1672-1679.
133. Rivas-Santiago B., Castaneda-Delgado J.E., Rivas Santiago C.E., Waldbrook M., Gonzalez-Curiel I., Leon-Contreras J.C., Enciso-Moreno J.A., del Villar V., Mendez-Ramos J., Hancock R.E.W., Hernandez-Pando R., (2013) Ability of innate defence regulator peptides IDR-1002, IDR-HH2 and IDR-1018 to protect against Mycobacterium tuberculosis infections in animal models. PLoS ONE; 8: e59119.
134. Achtman A.H., Pilat S., Law C.W., Lynn D.J., Janot L., Mayer M.L., Ma S., Kindrachuk J., Finlay B.B., Brinkman F.S., Smyth G.K., Hancock R.E.W., Schofield L., (2012) Effective adjunctive therapy by an innate defense regulatory peptide in a pre-clinical model of severe malaria. Sci Trasl Med; 4: 135ra64.
135. Faber C., Stallmann H.P., Lyaruu D.M., Joosten U., von Eiff C., van Nieuw Amerongen A., Wuisman P.I., (2005) Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model. Antimicrob Agents Chemother; 49: 2438-2444.
136. Velden W.J., van Iersel T.M., Blijlevens N.M., Donnelly J.P., (2009) Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). BMC Med; 7: 44.
137. Papareddy P., Kalle M., Sorensen O.E., Malmsten M., Morgelin M., Schmidtchen A., (2013) The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis. PLoS Pathog; 9: e1003803.
138. Easton D.M., Nijnik A., Mayer M.L., Hancock R.E.W., (2009) Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol; 27: 582-590.
139. World Health Organization (2013) Diarrhoeal disease. Fact sheet No. 330. http://www.who.int/mediacentre/factsheets/fs330/en/.
140. Mandal S.M., Dey S., Mandal M., Sarkar S., Maria-Neto S., Franco O.L., (2009) Identification and structural insights of three novel antimicrobial peptides isolated from green coconut water. Peptides; 30: 633-637.
141. Ciglenecki I., Bichet M., Tena J., Mondesir E., Bastard M., Tran N.T., Antierens A., Staderini N., (2013) Cholera in pregnancy: outcomes from a specialized cholera treatment unit for pregnant women in Léogâne, Haiti. PLoS Negl Trop Dis; 7: e2368.
142. Sulakvelidze A., Alavidze Z., Morris J.G. Jr, (2001) Bacteriophage therapy. Antimicrob Agents Chemother; 45: 649-659.
143. d'Herelle F., (1917) Surun microbe invisible antagoniste des bacteries dysenteriques. C R Acad Sci; 165: 373-375.
144. Hausler T., (2006) Viruses versus superbugs. A solution to the antibiotic crisis?. New York: Palgrave Macmillan.
145. Skurnika M., Strauch E., (2006) Phage therapy: facts and fiction. Intern J Med Microbiol; 296: 5-14.
146. Inal J.M., (2003) Phage therapy: a reappraisal of bacteriophages as antibiotics. Arch Immunol Ther Exp (Warsz); 51: 237-244.
147. Brüssow H., Canchaya C., Hardt W.D., (2004) Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. Microbiol Mol Biol Rev; 68: 560-602.
148. Mandal S.M., Roy A., Ghosh A.K., Hazra T.K., Basak A., Franco O.L., (2014) Challenges and future prospects of antibiotic therapy: from peptides to phages utilization. Front Pharmac; 5: 105.
149. Khairnar K., Raut M.P., Chandekar R.H., Sanmukh S.G., Paunikar W.N., (2013) Novel bacteriophage therapy for controlling metallo-beta-lactamase producing Pseudomonas aeruginosa infection in catfish. BMC Vet Res; 26: 264.
150. Drilling A., Morales S., Boase S., Jervis-Bardy J., James C., Jardeleza C., Tan N.C., Cleland E., Speck P., Vreugde S., Wormald P.J., (2014) Safety and efficacy of topical bacteriophage and ethylenediaminetetraacetic acid treatment of Staphylococcus aureus infection in a sheep model of sinusitis. Int Forum Allergy Rhinol; 4: 176-186.
151. Lungren M.P., Christensen D., Kankotia R., Falk I., Paxton B.E., Kim C.Y., (2013) Bacteriophage K for reduction of Staphylococcus aureus biofilm on central venous catheter material. Bacteriophage; 3: e26825.
152. Parfitt T., (2005) Georgia: an unlikely stronghold for bacteriophage therapy. Lancet; 365: 2166-2167.
153. Thiel K., (2004) Old dogma, new tricks-21st Century phage therapy. Nat Biotechn; 22: 31-36.
154. Lu T.K., Collins J.J., (2009) Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci USA; 106: 4629-4634.
155. Westwater C., Kasman L.M., Schofield D.A., Werner P.A., Dolan J.W., Schmidt M.G., Norris J.S., (2003) Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother; 47: 1301-1307.
156. Walsh C.J., Guinane C.M., O'Toole P.W., Cotter P.D., (2014) Beneficial modulation of the gut microbiota. FEBS Lett; 588: 4120-4130.
157. Lilly D.M., Stillwell R.H., (1965) Probiotics: growth-promoting factors produced by microorganisms. Science; 147: 747-748.
158. Volzing K., Borrero J., Sadowsky M.J., Kaznessis Y.N., (2013) Antimicrobial peptides targeting gram-negative pathogens, produced and delivered by lactic acid bacteria. ACS Synth Biol; 2: 643-650.
159. Lu L., Walker W.A., (2001) Pathologic and physiologic interactions of bacteria with the gastrointestinal epithelium. Am J Clin Nutr; 73: 1124-1130.
160. Carr F.J., Chill D., Maida N., (2002) The lactic acid bacteria: a literature survey. Crit Rev Microbiol; 28: 281-370.
161. Hassan M., Kjos M., Nes I.F., Diep D.B., Lotfipour F., (2012) Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance. J Appl Microbiol; 113: 723-736.
162. Mandal S.M., Silva O.N., Franco O.L., (2014) Recombinant probiotics with antimicrobial peptides: a dual strategy to improve immune response in immunocompromised patients. Drug Discov Today; 19: 1045-1050.
163. Petschow B., Doré J., Hibberd P., Dinan T., Reid G., Blaser M., Cani P.D., et al,. (2013) Probiotics, prebiotics, and the host microbiome: the science of translation. Ann N Y Acad Sci; 1306: 1-17.
164. Tahlan K., Park H.U., Wong A., Beatty P.H., Jensen S.E., (2004) Two sets of paralogous genes encode the enzymes involved in the early stages of clavulanic acid and clavam metabolite biosynthesis in Streptomyces clavuligerus. Antimicrob Agents Chemother; 48: 930-939.
165. Totir M.A., Helfand M.S., Carey M.P., Sheri A., Buynak J.D., Bonomo R.A., Cary P.R., (2007) Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 β-lactamase. Biochemistry; 46: 8980-8987.
166. Carlier M., Carrette S., Stove V., Verstraete A.G., De Waele J.J., (2014) Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course. Int J Antimicrob Agents; 14: S0924-S8579.
167. Coleman K., Levasseur P., Girard A.M., Borgonovi M., Miossec C., Merdjan H., Drusano G., Shlaes D., Nichols W.W., (2014) The activity of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother; 58: 3366-3372.
168. Castanheira M., Williams G., Jones R.N., Sader H.S., (2014) Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying β-lactamases prevalent in the United States. Microb Drug Resist; 20: 436-440.
169. Livermore D.M., Mushtaq S., Warner M., Zhang J., Maharjan S., Doumith M., Woodford N., (2011) Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing enterobacteriaceae. Antimicrob Agents Chemother; 55: 390-394.
170. Hiraiwa Y., Morinaka A., Fukushima T., Kudo T., (2013) Metallo-β-lactamase inhibitory activity of 3-alkyloxy and 3-amino phthalic acid derivatives and their combination effect with carbapenem. Bioorg Med Chem; 21: 5841-5850.
171. Toney J.H., Hammond G.G., Fitzgerald P.M.D., Sharma N., Balkovec J.M., Rouen G.P., Olson S.H., Hammond M.L., Greenlee M.L., Gao Y.D., (2001) Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo-β-lactamase. J Biol Chem; 276: 31913-31918.
172. Goldstein E.J., Citron D.M., Tyrrell K.L., Merriam C.V., (2013) In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria. Antimicrob Agents Chemother; 57: 2620-2630.
173. Fontaine F., Hequet A., Voisin-Chiret A.S., Bouillon A., Lesnard A., Cresteil T., Jolivalt C., Rault S., (2014) First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump. J Med Chem; 57: 2536-2548.
174. Hequet A., Burchak O.N., Jeanty M., Guinchard X., Le Pihive E., Maigre L., Bouhours P., Schneider D., Maurin M., Paris J.M., Denis J.N., Jolivalt C., (2014) 1-(1H-Indol-3-yl)ethanamine derivatives as potent Staphylococcus aureus NorA efflux pump inhibitors. Chem Med Chem; 9: 1534-1545.
175. Kalia N.P., Mahajan P., Mehra R., Nargotra A., Sharma J.P., Koul S., Khan I.A., (2012) Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus. J Antimicrob Chemother; 67: 2401-2408.
176. Sabatini S., Gosetto F., Serritella S., Manfroni G., Tabarrini O., Iraci N., Brincat J.P., Carosati E., Villarini M., Kaatz G.W., Cecchetti V., (2012) Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors. J Med Chem; 55: 3568-3572.
177. Sabatini S., Gosetto F., Manfroni G., Tabarrini O., Kaatz G.W., Patel D., Cecchetti V., (2011) Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump. J Med Chem; 54: 5722-5736.
178. Brincat J.P., Carosati E., Sabatini S., Manfroni G., Fravolini A., Raygada J.L., Patel D., Kaatz G.W., Cruciani G., (2011) Discovery of novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. J Med Chem; 54: 354-365.
179. Thota N., Reddy M.V., Kumar A., Khan I.A., Sangwan P.L., Kalia N.P., Koul J.L., Koul S., (2010) Substituted dihydronaphthalenes as efflux pump inhibitors of Staphylococcus aureus. Eur J Med Chem; 45: 3607-3616.